PTC Therapeutics
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell PTCT and other ETFs, options, and stocks.About PTCT
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
PTCT Key Statistics
Stock Snapshot
The current PTC Therapeutics(PTCT) stock price is $77.65, with a market capitalization of 6.23B. The stock trades at a price-to-earnings (P/E) ratio of 8.86.
As of 2025-12-05, PTC Therapeutics(PTCT) stock has fluctuated between $76.54 and $79.00. The current price stands at $77.65, placing the stock +1.5% above today's low and -1.7% off the high.
PTC Therapeutics(PTCT) shares are trading with a volume of 111.34K, against a daily average of 3.42M.
During the past year, PTC Therapeutics(PTCT) stock moved between $35.95 at its lowest and $87.50 at its peak.
During the past year, PTC Therapeutics(PTCT) stock moved between $35.95 at its lowest and $87.50 at its peak.
PTCT News
New insider activity at PTC Therapeutics ( (PTCT) ) has taken place on December 3, 2025. TipRanks Cyber Monday Sale Claim 60% off TipRanks Premium for data-back...
PTC’s turnaround quarter is raising eyebrows—here’s why one major investor just doubled down. PTC Therapeutics (PTCT 3.48%) saw California-based Palo Alto Inve...
Key Points San Diego-based Tang Capital Management added 400,000 PTC Therapeutics shares in the third quarter. The value of the position increased by $38.3 mi...
Analyst ratings
60%
of 15 ratingsMore PTCT News
PTC Therapeutics (PTCT) has been under the spotlight recently, with investors chatting about its steady gains over the past month. The company’s stock has climb...
Focused on rare disease therapies, this biotech company reported a significant insider sale amid strong recent share price gains. Director Emma Reeve of PTC Th...
